This study shows that sigma-2 receptor modulators increase LDL uptake in RPE cells via TMEM97 and LDLR, supporting their potential therapeutic use in dry AMD.

Experimental Eye Research · Feb 25, 2026Peer-reviewedCell Biology

Multi-omics comparative analyses of synucleinopathy models reveal distinct targets and relevance for drug development

Britney N. Lizama, Rick S. Shin, Hilary A. North, Gary C. Look, Aidan Reaver, Kiran Pandey, Duc M. Duong, Nicholas T. Seyfried, Anthony O. Caggiano, Mary E. Hamby

The paper compares two rat synucleinopathy models using multi-omics data to identify disease mechanisms and drug targets relevant to Parkinson's disease.

bioRxiv · Jun 20, 2025 · PreprintNeuroscience

An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease

Britney N. Lizama, H.A. North, K. Pandey, C. Williams, Duc M. Duong, E. Cho, V. Di Caro, L. Ping, Kaj Blennow, Henrik Zetterberg, James J. Lah, Allan I. Levey, Michael Grundman, Anthony O. Caggiano, Nicholas T. Seyfried, Madison Hamby

This paper reports exploratory CSF proteomics data from a Phase 2 trial of CT1812 in Alzheimer's disease, identifying pharmacodynamic biomarkers and mechanistic insights.

Neurobiology of Disease · Jun 22, 2024Peer-reviewedNeuroscience

Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease

Martí Colom‐Cadena, Jamie Toombs, Elizabeth M. Simzer, Kristján Holt, Robert I. McGeachan, Jane Tulloch, Rosemary J. Jackson, James H. Catterson, Maxwell P Spires-Jones, Jamie L. Rose, Lora Waybright, Anthony O. Caggiano, Declan King, Francesco Gobbo, Caitlin Davies, , Tara L. Spires‐Jones

The paper identifies transmembrane protein 97 as a synaptic receptor for amyloid beta in human Alzheimer's disease using advanced microscopy and drug intervention studies.

Acta Neuropathologica · Feb 6, 2024Peer-reviewedNeuroscience